Pharmacologic Drug Detection and Self-Reported Adherence in the HPTN069/ACTG5305 Phase II PrEP TrialStanley Evan Cooper, Roy M. Gulick, K. Rivet Amico et al.|AIDS and Behavior|2024Cited by 1
Cabotegravir Maintains Protective Efficacy in the Setting of Bacterial Sexually Transmitted Infections: A Secondary Analysis of HPTN 083Meredith E. Clement, Richard Novák, Brett Hanscom et al.|Clinical Infectious Diseases|2024Cited by 0